Prevalencia de las manifestaciones extraintestinales, factores de riesgo y manejo terapéutico en los pacientes con enfermedad inflamatoria intestinal

Gallego, Esther Merino; Sánchez, Fernando Sánchez

doi:10.1016/j.gastrohep.2021.11.008

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The studies included herein did not analyse the impact of the disease according to severity. However, several studies suggested that more severe forms of the disease are associated with greater presence of EIMs and resource use [ 34 , 39 , 73 ]. In line with this, a pan-European study suggested that more severe phenotypes result in a significantly higher mean annual cost in both CD and UC [ 69 ].…”

Section: Discussionmentioning

confidence: 99%

Epidemiological, Clinical, Patient-Reported and Economic Burden of Inflammatory Bowel Disease (Ulcerative colitis and Crohn’s disease) in Spain: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Introduction This study describes the epidemiological, clinical, patient-reported and economic burden of inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), in Spain. Methods A systematic review was performed of observational studies reporting the epidemiological, clinical, patient-reported and economic burden of IBD in the Spanish population, from 2011 to 2021. Original articles and conference abstracts published in English or Spanish were eligible. Results A total of 45 publications were included in the review. The incidence of IBD in adults ranged from 9.6 to 44.3 per 100,000 inhabitants (4.6 to 18.5 for CD and 3.4 to 26.5 for UC). The incidence increased between 1.5- and twofold from 2000 to 2016 (regionally). Up to 6.0% (CD) and 3.0% (UC) IBD-associated mortality was reported. Disease onset predominantly occurs between 30 and 40 years (more delayed for UC than CD). Most frequently reported gastrointestinal manifestations are rectal bleeding in UC and weight loss in CD. Extraintestinal manifestations (EIM) have been described in up to 47.4% of patients with CD and 48.1% of patients with UC. Psychiatric comorbidities were frequently reported in both CD and UC (depression up to 20% and anxiety up to 11%). Reduced health-related quality of life (HRQoL) compared to the general population was reported. Significant symptomatology was associated with high levels of anxiety, depression, stress and lower HRQoL. Main healthcare resources reported were emergency department visits (24.0%), hospitalization (14.7%), surgery (up to 11%) and use of biologics (up to 60%), especially in CD. Direct and indirect annual costs per patient with UC were €1754.1 and €399.3, respectively. Conclusion Patients with CD and UC present a high disease burden which negatively impacts their HRQoL, leading to elevated use of resources. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-023-02473-6.

show abstract